Company Profile
Allogene Therapeutics Stock Price, News & Catalysts
- Ticker:
- ALLO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.67 USD (-4.17%)
Close
Last updated: November 19, 2026
708M USD
Market cap
Why the stock is moving
The latest monitored company update is “Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access.” The corresponding closing-price reaction is not yet available.
Company overview
Allogeneic CAR T Company
Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing.
Cema-Cel
Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for outpatient administration. It has received FDA Regenerative Medicine Advanced Therapy and Fast Track designations in first-line large B-cell lymphoma consolidation.
MRD-Guided Lymphoma Treatment
The pivotal Phase 2 ALPHA3 study evaluates cema-cel in first-line large B-cell lymphoma patients who remain minimal residual disease-positive after standard treatment. This approach seeks to intervene before overt clinical relapse.
ALLO-329
ALLO-329 is a dual-targeting CD19/CD70 AlloCAR T candidate for autoimmune diseases. Its Dagger technology is designed to reduce host rejection and potentially limit dependence on conventional chemotherapy-based lymphodepletion.
Future catalysts
- Updated Phase 1 RESOLUTION data for ALLO-329 at ACR Convergence on November 9, 2026.
- Next ALPHA3 clinical update in mid-2027.
- Completion of ALPHA3 enrollment by year-end 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allogene Therapeutics (ALLO)?
Allogene Therapeutics (ALLO) most recently closed at 0.67 USD, a -4.17% move versus the previous session.
What is the market cap of Allogene Therapeutics (ALLO)?
Allogene Therapeutics currently has a market capitalization of 708M USD on BioPharmSignal.
What does Allogene Therapeutics do?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for...
On which exchange is ALLO stock listed?
Allogene Therapeutics (ALLO) is associated with NASDAQ, United States, Biopharma.
What is ALLO-329?
Updated Phase 1 RESOLUTION data for ALLO-329 at ACR Convergence on November 9, 2026.
Which conditions is Allogene Therapeutics targeting with ALLO-329?
Allogene Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Allogene Therapeutics describe recent progress with ALLO-329?
Updated Phase 1 RESOLUTION data for ALLO-329 at ACR Convergence on November 9, 2026.
What is Allogeneic?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease.
